Argenx reports positive Phase 2 results for FB102 in celiac disease, plans Phase 3 trial
Argenx announced its experimental drug FB102 met the primary endpoint in a Phase 2 study for celiac disease, providing first evidence that blocking CD122 can prevent gluten-induced intestinal damage. The company plans to advance the drug into Phase 3 development, though the news was overshadowed by a simultaneous setback in Sjögren's disease that sent shares falling.
